B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

per Shah, Nina, Chari, Ajai, Scott, Emma, Mezzi, Khalid, Usmani, Saad Z.
Publicat a Leukemia (2020)

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

per Chari, Ajai, Mezzi, Khalid, Zhu, Shao, Werther, Winifred, Felici, Diana, Lyon, Alexander R.
Publicat a BMC Cancer (2016)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

per Landgren, Ola, Sonneveld, Pieter, Jakubowiak, Andrzej, Mohty, Mohamad, Iskander, Karim S., Mezzi, Khalid, Siegel, David S.
Publicat a Leukemia (2019)

How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

per Cohen, Adam D., Raje, Noopur, Fowler, Jessica A., Mezzi, Khalid, Scott, Emma C, Dhodapkar, Madhav V.
Publicat a Clin Cancer Res (2019)

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

per Reece, Donna, Song, Kevin, LeBlanc, Richard, Mezzi, Khalid, Olujohungbe, Ade, White, Darrell, Zaman, Faraz, Belch, Andrew
Publicat 2013

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting

per Rifkin, Robert M., Medhekar, Rohan, Amirian, E. Susan, Aguilar, Kathleen M., Wilson, Thomas, Boyd, Marley, Mezzi, Khalid, Panjabi, Sumeet
Publicat a Ther Adv Hematol (2019)

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

per Dimopoulos, Meletios, Siegel, David, White, Darrell J., Boccia, Ralph, Iskander, Karim S., Yang, Zhao, Kimball, Amy S., Mezzi, Khalid, Ludwig, Heinz, Niesvizky, Ruben
Publicat a Blood (2019)

Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress

per Wei, Andrew H., Roberts, Andrew W., Spencer, Andrew, Rosenberg, Aaron Seth, Siegel, David, Walter, Roland B., Caenepeel, Sean, Hughes, Paul, McIver, Zach, Mezzi, Khalid, Morrow, Phuong Khanh, Stein, Anthony
Publicat a Blood Rev (2020)

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

per Gormley, Nicole, Fashoyin-Aje, Lola, Locke, Trevan, Unger, Joseph M., Little, Richard F., Nooka, Ajay, Mezzi, Khalid, Popa-McKiver, Mihaela, Kobos, Rachel, Biru, Yelak, Williams, Tiffany H., Anderson, Kenneth C.
Publicat a Blood Cancer Discov (2021)

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

per Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Publicat a Cancer Med (2020)

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

per Facon, Thierry, Niesvizky, Ruben, Mateos, Maria-Victoria, Siegel, David, Rosenbaum, Cara, Bringhen, Sara, Weisel, Katja, Ho, P. Joy, Ludwig, Heinz, Kumar, Shaji, Wang, Kenneth, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra, Mezzi, Khalid, Goldrick, Amanda, Tekle, Christina, Dimopoulos, Meletios A.
Publicat a Blood Adv (2020)